Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients

AIDS

Volumn 24, Issue 13, 2010, Pages 2019-2027

  Squires, Kathleen E ^a   Young, Benjamin ^b   Dejesus, Edwin ^c   Bellos, Nicholaos ^d   Murphy, Daniel ^e   Zhao, Henry H ^f   Patel, Lisa G ^f   Ross, Lisa L ^f   Wannamaker, Paul G ^f   Shaefer, Mark S ^g  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c ORLANDO IMMUNOLOGY CENTER   (United States)

^d Southwest Infectious Disease Associates   (United States)

^e Clinique Medicale LActuel   (Canada)

^f GLAXOSMITHKLINE   (United States)

^g VIIV HEALTHCARE   (United States)

Author keywords

abacavir; antiretroviral therapy; atazanavir; lamivudine; ritonavir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; LAMIVUDINE PLUS ZIDOVUDINE; RITONAVIR; VIRUS RNA;

ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VOMITING;

ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 77955415316     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833bee1b     Document Type: Article

References (14)

1. Crum NF, Riffenburgh RH, Wegner S, Agan BK, Tasker SA, Spooner KM, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006; 41:194-200.
2. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
3. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; 2009. pp. 1-161. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. [Accessed4December 2009]
4. Hammer SM, Eron JJ, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
5. Carr A. Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov 2003; 2:624-634.
6. Becker S. The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy. Expert Opin Investig Drugs 2003; 12:410-412.
7. Gatti G, Di Biagio A, Casazza R, De Pascalis C, Bassetti M, Cruciani M, et al. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 1999; 13:2083-2089.
8. Squires K, Young B, DeJesus E, Bellos N, Murphy D, Sutherland-Phillips D, et al. Atazanavir/ritonavir (ATV/r)Rabacavir/lami-vudine (ABC/3TC) in antiretroviral (ART)-naive HIV-1 infected HLA-BM5701 negative subjects demonstrates efficacy and safety: the ARIES trial (in press).
9. Young B, Squires K, Patel P, DeJesus E, Bellos N, Berger D, et al. First large, multicenter, open-label study utilizing HLA-BM5701 screening for abacavir hypersensitivity in North America. AIDS 2008; 22:1673-1675.
10. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-285.
11. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285:2486-2497.
12. Delfraissy JF, Moreno S, Sanz-Moreno J, Carosi G, Pokrovsky V, Lazzarin A, et al. Efficacy and safety of 48 weeks maintenance with once-daily ATV vs. ATV/r in patients with viral load
13. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisaktd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antire-troviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-655.
14. Elion R, DeJesus E, Sension M, Berger D, Towner W, Richmond G, et al. Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretrovir-al-nä?ve patients: a 48 week pilot study. HIV Clin Trials 2008; 9:152-163.